Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.
Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, Stamatoullas A, Fornecker L, Deau B, Gastinne T, Reman O, Gaillard I, Borel C, Brice P, Fermé C. Van Den Neste E, et al. Among authors: edeline v. Haematologica. 2013 Aug;98(8):1185-95. doi: 10.3324/haematol.2012.072090. Haematologica. 2013. PMID: 23904236 Free PMC article. Review.
Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials.
Meignan M, Itti E, Bardet S, Lumbroso J, Edeline V, Olivier P, Borght TV, Reman O, Karcher G, Mundler O, Mounier N, Ricci R, Federico M, Raemaekers J, André M. Meignan M, et al. Among authors: edeline v. J Clin Oncol. 2009 Jun 1;27(16):2739-41. doi: 10.1200/JCO.2009.22.4089. Epub 2009 Apr 27. J Clin Oncol. 2009. PMID: 19398565 No abstract available.
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. Among authors: edeline v. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V. Berriolo-Riedinger A, et al. Among authors: edeline v. Cancer Radiother. 2018 Sep;22(5):393-400. doi: 10.1016/j.canrad.2018.06.001. Epub 2018 Jul 20. Cancer Radiother. 2018. PMID: 30033076 Review.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M. Casasnovas RO, et al. Among authors: edeline v. Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658935 Clinical Trial.
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Sibon D, Bonnet C, Berriolo-Riedinger A, Edeline V, Parrens M, Damotte D, Coso D, André M, Meignan M, Rossi C. Casasnovas RO, et al. Among authors: edeline v. J Clin Oncol. 2022 Apr 1;40(10):1091-1101. doi: 10.1200/JCO.21.01777. Epub 2022 Jan 6. J Clin Oncol. 2022. PMID: 34990281 Free article. Clinical Trial.
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Stamatoullas A, Ghesquières H, Feugier P, André M, Le Bras F, Gac AC, Borel C, Gastinne T, Quittet P, Morschhauser F, Ribrag V, Guidez S, Nicolas-Virelizier E, Berriolo-Riedinger A, Vander Borght T, Edeline V, Brice P. Stamatoullas A, et al. Among authors: edeline v. Leuk Lymphoma. 2022 Dec;63(13):3063-3071. doi: 10.1080/10428194.2022.2107204. Epub 2022 Aug 17. Leuk Lymphoma. 2022. PMID: 35975738 Clinical Trial.
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, André M. Federico M, et al. Among authors: edeline v. J Clin Oncol. 2024 Jan 1;42(1):19-25. doi: 10.1200/JCO.23.01745. Epub 2023 Nov 15. J Clin Oncol. 2024. PMID: 37967311 Free PMC article. Clinical Trial.
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Aupérin A, Masson F, Bosq J, Edeline V, Fermé C, Pigneur F, Schlumberger M. Ribrag V, et al. Among authors: edeline v. Eur J Radiol. 2008 May;66(2):325-31. doi: 10.1016/j.ejrad.2007.06.014. Epub 2007 Jul 24. Eur J Radiol. 2008. PMID: 17651934
37 results